


$$C_{\varepsilon} \rightarrow E_{\varepsilon} = \frac{1}{\varepsilon} \nabla \phi_{\varepsilon} + \frac{1}{\varepsilon^2} \int_0^{\varepsilon} \int_0^{\cdot} \frac{1}{\sqrt{1 - t}} \frac{\partial}{\partial t} \phi_{\varepsilon}(t, \cdot) dt ds$$



References

1. Reardon S (2014) Infectious diseases: Smallpox watch. *Nature* 509: 22–24. <http://www.nature.com/news/infectious-diseases-smallpox-watch-1.15115>. Accessed 25 October 2015. doi: [10.1038/509022a](https://doi.org/10.1038/509022a) PMID: [24784198](https://pubmed.ncbi.nlm.nih.gov/24784198/)
2. Bidgood SR, Mercer J (2015) Cloak and Dagger: Alternative Immune Evasion and Modulation Strategies of Poxviruses. *Viruses* 7: 4800–4825. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576205/> Accessed 9 September 2015. doi: [10.3390/v7082844](https://doi.org/10.3390/v7082844) PMID: [26308043](https://pubmed.ncbi.nlm.nih.gov/26308043/)
3. Thorne SH (2014) Immunotherapeutic potential of oncolytic vaccinia virus. *Front Oncol* 4: 155. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4060052/> Accessed 25 October 2015. doi: [10.3389/fonc.2014.00155](https://doi.org/10.3389/fonc.2014.00155) PMID: [24987615](https://pubmed.ncbi.nlm.nih.gov/24987615/)
4. Ndiaye BP, Thienemann F, Ota M, Landry BS, Camara M, et al. (2015) Safety, immunogenicity, and efficacy of the candidate tuberculosis vaccine MVA85A in healthy adults infected with HIV-1: a randomised, placebo-controlled, phase 2 trial. *Lancet Respir Med* 3: 190–200. <http://www.sciencedirect.com/science/article/pii/S2213260015000375>. doi: [10.1016/S2213-2600\(15\)00037-5](https://doi.org/10.1016/S2213-2600(15)00037-5) PMID: [25726088](https://pubmed.ncbi.nlm.nih.gov/25726088/)
5. Hodgson SH, Ewer KJ, Bliss CM, Edwards NJ, Rampling T, et al. (2014) Evaluation of the Efficacy of ChAd63-MVA Vectored Vaccines Expressing Circumsporozoite Protein and ME-TRAP Against Controlled Human Malaria Infection in Malaria-Naive Individuals. *J Infect Dis*: 1–11. <http://www.ncbi.nlm.nih.gov/pubmed/25336730>.
6. Smith GL, Benfield CTO, Maluquer de Motes C, Mazzon M, Ember SWJ, et al. (2013) Vaccinia virus immune evasion: Mechanisms, virulence and immunogenicity. *J Gen Virol* 94: 2367–2392. doi: [10.1099/vir.0.055921-0](https://doi.org/10.1099/vir.0.055921-0) PMID: [23999164](https://pubmed.ncbi.nlm.nih.gov/23999164/)
7. Annadurai K, Danasekaran R, Mani G (2014) Global eradication of guinea worm disease: Toward a newer milestone. *J Res Med Sci* 19: 1207–1208. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4333534/> Accessed 21 April 2015. PMID: [25709667](https://pubmed.ncbi.nlm.nih.gov/25709667/)
8. Callahan K, Bolton B, Hopkins DR, Ruiz-Tiben E, Withers PC, et al. (2013) Contributions of the Guinea worm disease eradication campaign toward achievement of the Millennium Development Goals. *PLoS Negl Trop Dis* 7: e2160. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667764/>
